2026 marks a major wave of pharmaceutical patent expirations for blockbuster drugs like Merck’s Januvia/Janumet, Pfizer’s Xeljanz, Novo Nordisk’s Ozempic, and Eliquis (BMS/Pfizer), leading to generic and biosimilar competition and significant revenue erosion.123
Industry analyses project $236 billion in annual global revenue at risk from 2025-2030 patent cliffs, targeting complex biologics and specialized therapies unlike prior small-molecule cliffs.3
Generic launches typically cause >90% price declines, expanding access but pressuring pharma revenues; companies counter with patent extensions, evergreening, and R&D shifts to biologics and novel therapies.1
FDA initiatives include a 2025 pilot for fast-tracking U.S.-made generics and streamlined biosimilar approvals to accelerate competition post-expiration.1
Pharma strategies involve M&A acceleration, defensive innovations (e.g., Merck’s Keytruda subcutaneous shift), and portfolio maturation to offset losses amid IRA negotiations and policy scrutiny.2356
Sources:
1. https://intuitionlabs.ai/articles/drug-patent-expirations-2026
2. https://www.globenewswire.com/news-release/2026/01/12/3216891/0/en/The-Succeeding-Patent-Edge-Strategic-Implications-for-Pharma-Revenue-Portfolios-and-Innovation.html
3. https://www.drugpatentwatch.com/blog/the-data-driven-guide-to-winning-the-2026-patent-cliff/
5. https://inquisitiveminds.bristows.com/post/102midb/off-the-cliff-into-the-deal-room-pharma-ma-in-2026-and-beyond
6. https://www.pharmaceuticalcommerce.com/view/patent-cliff-pressure-to-sustain-pharma-momentum-2026